

Request Information

Permalink

# Robust Genome Engineering in Primary Human T Cells using CRISPR/Cas9 Ribonucleoproteins

Tech ID: 24858 / UC Case 2015-118-0

## INVENTION NOVELTY

This invention enables highly effective experimental and therapeutic genomic engineering of primary human T cells and other hematopoietic cells with CRISPR/Cas9 ribonucleoprotein (RNP) technology.

## VALUE PROPOSITION

CRISPR/Cas9-mediated genome editing provides an exceptional opportunity to engineer human T cells for research and therapeutic purposes, including cell-based therapies for cancer, viral infections and autoimmune diseases. However, therapeutic applications of CRISPR/Cas9 have been limited until now by inefficient DNA editing and inability to perform targeted DNA sequence replacement in human T cells. This invention augments the efficiency of CRISPR/Cas9-mediated genome editing in human T cells and raises the prospect of the therapeutic application of gene correction in T cells for treatment of myriad human diseases.

Additional advantages of this invention include:

- ▶ First CRISPR-mediated homology directed repair (HDR) in human immune cells could allow therapeutic editing of disease mutations in patient cells and introduction of specific sequences into TCR and CAR-transduced T cells.
- ▶ Strict temporal control over genome editing with Cas9 RNPs could increase the CRISPR safety profile for therapeutic applications.

## TECHNOLOGY DESCRIPTION

UCSF researchers have developed a powerful Cas9 RNP-based technology that uses purified Cas9 ribonucleoproteins (RNP) for successful and efficient genome editing in primary human CD4<sup>+</sup> T cells. Cas9 protein pre-complexed with a single guide RNA (sgRNA) is introduced as an RNP into human T cells by transient electroporation. The active complexes enabled the first successful Cas9-mediated homology directed repair (HDR) in primary human T cells. Cas9 RNPs have allowed generation of ‘knock-in’ primary human T cells with targeted genetic replacement of specific nucleotides, which was previously unattainable.

## APPLICATION

- 1) Unprecedented flexibility to ‘knock-out’ and ‘knock-in’ specific genetic elements in engineered T cells for cancer immunotherapy

## CONTACT

Todd M. Pazdera  
[todd.pazdera@ucsf.edu](mailto:todd.pazdera@ucsf.edu)  
tel: [415-502-1636](tel:415-502-1636).



## INVENTORS

- ▶ Bluestone, Jeffrey A.
- ▶ Doudna, Jennifer A.
- ▶ Lin, Steven
- ▶ Marson, Alexander
- ▶ Schumann, Kathrin

## OTHER INFORMATION

### KEYWORDS

CRISPR/Cas9, Primary human T cells, Genome engineering, Cas9 ribonucleoprotein (RNP), Gene correction/replacement, Homology-directed repair (HDR)

### CATEGORIZED AS

- ▶ **Medical**
- ▶ [Gene Therapy](#)
- ▶ [Research Tools](#)

2) New opportunity for therapeutic gene correction for primary immune deficiencies, treatment of infections and autoimmune diseases

3) Diverse research applications examining the function of coding and non-coding genetic variation in human immune regulation

► [Therapeutics](#)

RELATED CASES

2015-118-0

STAGE OF DEVELOPMENT

Proof of principle

RELATED MATERIALS

► Not available at this time

DATA AVAILABILITY

In vitro human data

PATENT STATUS

Country	Type	Number	Dated	Case
New Zealand	Issued Patent	733807	09/03/2024	2015-118
Rep Of Korea	Issued Patent	10-2605464	11/20/2023	2015-118
Japan	Issued Patent	7356750	09/27/2023	2015-118
Singapore	Issued Patent	11201706059S	12/20/2022	2015-118
Japan	Issued Patent	7114117	07/29/2022	2015-118
Australia	Issued Patent	2016211161	07/14/2022	2015-118
Hong Kong	Issued Patent	HK1248755	01/28/2022	2015-118
China	Issued Patent	ZL201680016762.8	10/15/2021	2015-118
Germany	Issued Patent	602016058406.9	05/26/2021	2015-118
Spain	Issued Patent	3250693	05/26/2021	2015-118
France	Issued Patent	3250693	05/26/2021	2015-118
United Kingdom	Issued Patent	3250693	05/26/2021	2015-118
Italy	Issued Patent	502021000066404	05/26/2021	2015-118
Japan	Issued Patent	6886404	05/18/2021	2015-118
Israel	Issued Patent	253498	12/01/2020	2015-118
European Patent Office	Published Application	3929296	12/29/2021	2015-118
United States Of America	Published Application	<a href="#">20190388469</a>	12/26/2019	2015-118
Canada	Published Application			2015-118

Additional Patents Pending

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- [XYZeq – Spatially-Resolved Single Cell Sequencing](#)
- [Anti-Dpp6 Car For Targeted Regulatory T Cell Therapy For Inflammation In Pancreatic Islets And Central Nervous System](#)

ADDRESS

UCSF  
Innovation Ventures

CONTACT

Tel:  
innovation@ucsf.edu

CONNECT

 Follow  Connect

600 16th St, Genentech Hall, S-272,  
San Francisco,CA 94158

<https://innovation.ucsf.edu>  
Fax:

© 2015 - 2024, The Regents of the University  
of California  
[Terms of use](#) [Privacy Notice](#)